StockDuty ← Dashboard Nov 11, 2026 12:59 AM ET
SignalEU/UK

Alamar Biosciences, Inc. (ALMR) Presents at 2026 UBS Global Healthcare Conference Transcript

High-priority alert based on source significance and keyword relevance.

What happened: Alamar Biosciences CFO Justin McAnear presented at the 2026 UBS Global Healthcare Conference, where UBS analyst Doug Schenkel noted the company's recent quarterly results, a collaboration with the U.K. Biobank and GSK, and a raised 2026 revenue outlook. Key numbers: Revenue up 68%. Consumables up 79%. Gross margin reached a record 61.5%. Why it matters: The analyst framed the discussion around durable growth driven by improved installed base economics, content expansion, and a more pronounced move into diagnostics.
Alamar Biosciences CFO Justin McAnear presented at the 2026 UBS Global Healthcare Conference, where UBS analyst Doug Schenkel noted the company's recent quarterly results, a collaboration with the U.K. Biobank and GSK, and a raised 2026 revenue outlook.
The analyst framed the discussion around durable growth driven by improved installed base economics, content expansion, and a more pronounced move into diagnostics.
Sources